Recon: Pfizer to Merge Off-Patent Drug Business With Mylan – Regulatory Focus

Recon: Pfizer to Merge Off-Patent Drug Business With Mylan  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Pfizer to Merge Its Off-Patent Drug Unit With Mylan …